Insmed (INSM Quick QuoteINSM - Free Report) reported $90.34 million in revenue for the quarter ended June 2024, representing a year-over-year increase of 17%. EPS of -$1.94 for the same period compares to -$1.78 a year ago.

The reported revenue represents a surprise of +2.71% over the Zacks Consensus Estimate of $87.96 million. With the consensus EPS estimate being -$1.22, the EPS surprise was -59.02%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Insmed performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- Japan

  : $21.11 million versus the two-analyst average estimate of $21.04 million.

• Revenue- Europe and rest of world

  : $5.44 million versus the two-analyst average estimate of $4.31 million.

• Revenue- U.S.

  $63.79 million versus $61.72 million estimated by two analysts on average.

View all Key Company Metrics for Insmed here>>>

Shares of Insmed have returned -2.9% over the past month versus the Zacks S&P 500 composite's -6.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.